News

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have jointly agreed on ten principles for good artificial intelligence (AI) practice across the…
Read More...

InterAx Biotech Ltd and Alveus Therapeutics Inc. have entered into a strategic research collaboration and licensing agreement aimed at developing a differentiated small-molecule therapy…
Read More...

Illumina has unveiled what it calls the world’s largest genome-wide genetic perturbation dataset, a major initiative designed to accelerate artificial intelligence–driven drug discovery…
Read More...

SciNeuro Pharmaceuticals has entered into a worldwide licensing and collaboration agreement with Novartis Pharma AG to advance a novel antibody program for the treatment of Alzheimer’s…
Read More...

NVIDIA and Eli Lilly and Company have announced the creation of a first-of-its-kind AI co-innovation lab designed to apply artificial intelligence to some of the most persistent…
Read More...

Atara Biotherapeutics has received a setback in its efforts to bring EBVALLO™ (tabelecleucel) to patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease…
Read More...

AbbVie has announced a voluntary agreement with the Trump administration aimed at expanding access and affordability of medicines for Americans while reinforcing the company’s long-term…
Read More...

AbbVie and RemeGen have entered into an exclusive global licensing agreement aimed at advancing RC148, a novel investigational bispecific antibody targeting both Programmed Cell Death-1…
Read More...

AbbVie and West Pharmaceutical Services have announced a definitive agreement under which AbbVie will acquire a device manufacturing facility and associated intellectual property from…
Read More...

Fortress Biotech, Inc. and its majority-owned subsidiary Cyprium Therapeutics have received a major regulatory milestone with the U.S. Food and Drug Administration’s approval of ZYCUBO®…
Read More...

BD (Becton, Dickinson and Company), a global leader in medical technology, has announced a $110 million investment to expand its production of prefillable syringes in the United States,…
Read More...

Solid Biosciences Inc., a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has reached two important milestones in the…
Read More...

Synaffix B.V., a Lonza company, and Sidewinder Therapeutics have entered into a multi-target licensing agreement aimed at developing first-in-class bispecific antibody-drug conjugate…
Read More...

Alessa Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration for Enolen®, its lead investigational therapy for the treatment of low- to…
Read More...

Cellenkos Inc., a clinical-stage biotechnology company developing off-the-shelf regulatory T cell (Treg) therapies, has received Orphan Drug Designation from the U.S. Food and Drug…
Read More...

Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK to develop, manufacture, and commercialize AGAMREE® (vamorolone) for the treatment of Duchenne…
Read More...

Eli Lilly and Company has reported positive topline results from its novel TOGETHER-PsA Phase 3b trial, demonstrating that the concomitant use of Taltz (ixekizumab) and Zepbound…
Read More...

Amgen has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom, in a deal valued at up to $840 million. The…
Read More...

Octapharma USA has received approval from the U.S. Food and Drug Administration for a new 2-gram presentation of Fibryga®, a human plasma-derived fibrinogen concentrate, expanding…
Read More...

GSK plc has reported positive results from two pivotal phase III clinical trials evaluating bepirovirsen, an investigational antisense oligonucleotide therapy for chronic hepatitis B…
Read More...